Anixa Biosciences
ANIX
55 hedge funds and large institutions have $17.3M invested in Anixa Biosciences in 2023 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 12 increasing their positions, 11 reducing their positions, and 5 closing their positions.
120% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 5
35% more capital invested
Capital invested by funds: $12.8M → $17.3M (+$4.45M)
12% more funds holding
Funds holding: 49 → 55 (+6)
1.7% more ownership
Funds ownership: 12.64% → 14.35% (+1.7%)
9% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 11
28% less call options, than puts
Call options by funds: $159K | Put options by funds: $220K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LNWTC
Laird Norton Wetherby Trust Company
Seattle,
Washington
|
+$1.24M |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$163K |
| 3 |
Jane Street
New York
|
+$146K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$124K |
| 5 |
Morgan Stanley
New York
|
+$122K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$80.5K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$80.5K |
| 3 |
JP Morgan Chase
New York
|
-$68.9K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$68.7K |
| 5 |
Squarepoint
New York
|
-$44.2K |
ANIX Hedge Fund Activity: Q4 2023 in Review
55 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Anixa Biosciences (ANIX) for Q4 2023, worth a combined $17.3M — up 35% from $12.8M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ANIX positions and 5 closed out — a net gain of 6 holders — while 12 added to existing stakes and 11 trimmed.
The largest buyer was Laird Norton Wetherby Trust Company, opening a new position worth an estimated $1.24M. The largest seller was Citadel Advisors, cutting an estimated $80.5K.
- 55 institutional investors held Anixa Biosciences (ANIX) as of Q4 2023, up from 49 in Q3 2023.
- Funds reported $17.3M of Anixa Biosciences stock for Q4 2023, up 35% quarter-over-quarter.
- 11 funds opened new Anixa Biosciences positions in Q4 2023 and 5 closed out, a net change of +6 holders.
- The largest Anixa Biosciences buyer in Q4 2023 was Laird Norton Wetherby Trust Company, an estimated $1.24M added.
- The largest Anixa Biosciences seller in Q4 2023 was Citadel Advisors, an estimated $80.5K sold.
Based on aggregated 13F filings for Q4 2023.